ACAD
- ACADIA Pharmaceuticals Inc.
()
Overview
Company Summary
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative treatments for central nervous system (CNS) disorders. The company is dedicated to addressing unmet medical needs in neurological and related disorders by developing therapies that target specific biological pathways in the brain.
ACADIA specializes in the field of neuropsychiatric disorders, with its primary focus on Parkinson's disease psychosis (PDP), Schizophrenia, and Alzheimer's disease. The company's flagship product, Nuplazid (pimavanserin), is the first and only FDA-approved treatment for hallucinations and delusions associated with PDP. Nuplazid works by selectively targeting serotonin receptors in the brain, providing a novel therapeutic approach for patients suffering from this debilitating condition.
ACADIA is continuously exploring the potential of its proprietary drug discovery platform to identify and develop new compounds that address other CNS disorders. The company's research and development efforts are directed towards advancing the understanding of the underlying neurobiology of these diseases and designing targeted therapies to offer a better quality of life for patients.
Furthermore, ACADIA Pharmaceuticals collaborates with various partners, including pharmaceutical companies, research institutions, and healthcare organizations, to expand its scientific knowledge, promote innovation, and gain regulatory approvals for its investigational products. These collaborations help ACADIA to leverage additional expertise and resources in order to accelerate the development and commercialization of potential treatments.
In summary, ACADIA Pharmaceuticals is dedicated to advancing the field of CNS disorders by developing innovative therapies and providing hope for patients suffering from conditions such as Parkinson's disease psychosis, Schizophrenia, and Alzheimer's disease.